Radiation for Treatment of Painful Bone Metastases.
Abstract Several variables may be considered when deciding on optimal modality of radiation therapy for each cancer patient with bone pain, including prognosis, tumor histology, location and extent of metastases, and association with cord compression. Hypofractionated external beam radiation therapy is as effective as a multiple fraction radiotherapy course in most cases, although retreatment rates are higher after a single dose of radiation. Stereotactic body radiation may be used in cases of oligometastatic disease, repeat irradiation, and radiation-resistant tumors. Radiopharmaceuticals may be used for pain fro...
Source: Clinical Prostate Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Shiloh R, Krishnan M Tags: Hematol Oncol Clin North Am Source Type: research

Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
This article is protected by copyright. All rights reserved. PMID: 29733466 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 7, 2018 Category: Cancer & Oncology Authors: Chen L, Cao H, Yu C, Feng Y Tags: Fundam Clin Pharmacol Source Type: research

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Conclusion The recommended phase II dose of birabresib in patients with select solid tumors is 80 mg once daily with continuous dosing. Birabresib has dose-proportional exposure and a favorable safety profile, with clinical activity observed in NMC. Future studies of birabresib must consider intermittent scheduling to possibly mitigate the toxicities of chronic dosing. PMID: 29733771 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 7, 2018 Category: Cancer & Oncology Authors: Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C Tags: J Clin Oncol Source Type: research

The impact of moderate wine consumption on the risk of developing prostate cancer.
Conclusions: In this meta-analysis, moderate wine consumption did not impact the risk of PCa. Interestingly, regarding the type of wine, moderate consumption of white wine increased the risk of PCa, whereas moderate consumption of red wine had a protective effect. Further analyses are needed to assess the differential molecular effect of white and red wine conferring their impact on PCa risk. PMID: 29713200 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 2, 2018 Category: Cancer & Oncology Authors: Vartolomei MD, Kimura S, Ferro M, Foerster B, Abufaraj M, Briganti A, Karakiewicz PI, Shariat SF Tags: Clin Epidemiol Source Type: research

PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy.
CONCLUSION: Our data suggest that elevated PYGO2 expression in primary prostate adenocarcinoma is a potential risk factor for BR. PMID: 28924059 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - May 1, 2018 Category: Cancer & Oncology Authors: Kao KR, Popadiuk P, Thoms J, Aoki S, Anwar S, Fitzgerald E, Andrews P, Voisey K, Gai L, Challa S, He Z, Gonzales-Aguirre P, Simmonds A, Popadiuk C Tags: J Clin Pathol Source Type: research

TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.
Abstract Receptor tyrosine kinases (RTKs) are important drivers of cancers. In addition to genomic alterations, aberrant activation of wild type RTKs plays an important role in driving cancer progression. However, the underlying mechanisms of how RTKs drive prostate cancer remain incompletely characterized. Here we show that non-proteolytic ubiquitination of RTK regulates its kinase activity and contributes to RTK-mediated prostate cancer metastasis. TRAF4, an E3 ubiquitin ligase, is highly expressed in metastatic prostate cancer. We demonstrated here that it is a key player in regulating RTK mediated prostate can...
Source: Clinical Prostate Cancer - May 1, 2018 Category: Cancer & Oncology Authors: Singh R, Karri D, Shen H, Shao J, Dasgupta S, Huang S, Edwards DP, Ittmann MM, O'Malley BW, Yi P Tags: J Clin Invest Source Type: research

Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer.
Conclusion Non-low-risk prostate cancer has a heritable pattern suggesting shared genetic factors, with the highest concordance among monozygotic twins. Our results suggest that a man whose brother has been diagnosed with a non-low-risk prostate cancer is at a clinically relevant increased risk of developing an aggressive prostate cancer himself. PMID: 29652556 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 13, 2018 Category: Cancer & Oncology Authors: Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O Tags: J Clin Oncol Source Type: research

PD-1/PD-L1 Pathway Inhibitors in Advanced Prostate Cancer.
Abstract INTRODUCTION: Pharmacological inhibition of immune checkpoint receptors or their ligands represents a transformative breakthrough in the management of multiple cancers. However, immune checkpoint inhibitors have yet to be FDA-approved for the management of metastatic prostate cancer (PCa), the commonest non-cutaneous malignancy in men. Areas covered: We review our current understanding of the PD-1/PD-L1 pathway in cancer, the use of anti-PD-1/PD-L1 therapeutics in PCa, and potential subgroups of PCa patients who may derive the greatest benefit from these agents (such as men with tumors that have expressio...
Source: Clinical Prostate Cancer - April 11, 2018 Category: Cancer & Oncology Authors: Isaacsson Velho P, Antonarakis ES Tags: Expert Rev Clin Pharmacol Source Type: research

GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2.
CONCLUSIONS: Our data demonstrated that GDF15 promoted the proliferation of cervical cancer cells via the up-regulation of CyclinD1 and CyclinE1 and the down-regulation of p21 through both the PI3K/AKT and MAPK/ERK signaling pathways in a complex with ErbB2. PMID: 29636108 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Li S, Ma YM, Zheng PS, Zhang P Tags: J Exp Clin Cancer Res Source Type: research

Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing.
CONCLUSIONS: smMIP capture provides an accurate, diagnostically sensitive, and economical means to diagnose MSI across cancer types without reliance on patient-matched normal material. The assay is readily scalable to large numbers of clinical samples, enables automated and quantitative analysis of microsatellite instability, and is readily standardized across clinical laboratories. PMID: 29632127 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Waalkes A, Smith N, Penewit K, Hempelmann J, Konnick EQ, Hause RJ, Pritchard CC, Salipante SJ Tags: Clin Chem Source Type: research

Re-expression of microRNA-4319 inhibits growth of prostate cancer via Her-2 suppression.
CONCLUSION: The growth and chemo-resistance of PC cells may be suppressed via re-expression of miR-4319 that inhibits Her-2 signaling. PMID: 29633185 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Lin X, Wang Y Tags: Clin Transl Oncol Source Type: research

Evaluation of changes in Bone Scan Index at different acquisition time-points in bone scintigraphy.
ng;rdh E Abstract Bone Scan Index (BSI) is a validated imaging biomarker to objectively assess tumour burden in bone in patients with prostate cancer, and can be used to monitor treatment response. It is not known if BSI is significantly altered when images are acquired at a time difference of 1 h. The aim of this study was to investigate if automatic calculation of BSI is affected when images are acquired 1 hour apart, after approximately 3 and 4 h. We prospectively studied patients with prostate cancer who were referred for bone scintigraphy according to clinical routine. The patients performed a ...
Source: Clinical Prostate Cancer - April 6, 2018 Category: Cancer & Oncology Authors: Kaboteh R, Minarik D, Reza M, Sadik M, Trägårdh E Tags: Clin Physiol Funct Imaging Source Type: research

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
Conclusion MP did not improve OS and increased deaths from other malignancies. The DFS and 10-year OS in these patients treated with 2 years of ADT were encouraging compared with historical estimates, although a definitive conclusion regarding value of ADT may not be made without a nontreatment control arm. PMID: 29624463 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 6, 2018 Category: Cancer & Oncology Authors: Hussain M, Tangen CM, Thompson IM, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM Tags: J Clin Oncol Source Type: research

Curing More Prostate Cancer: Thinking Through the Options.
PMID: 29624464 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 6, 2018 Category: Cancer & Oncology Authors: Sartor O Tags: J Clin Oncol Source Type: research

Is Serum Prostate-Specific Antigen a Reliable Prostate Cancer Marker in Liver Transplant Candidates.
In this study, we aimed to determine whether the prostate-specific antigen level is a reliable marker of prostate cancer in patients with hepatic insufficiency, based on evaluation of alterations in serum prostate-specific antigen levels after liver transplant in patients with hepatic insufficiency. MATERIALS AND METHODS: Medical records of all patients who underwent liver transplant at our hospital between January 2003 and June 2017 were retrospectively reviewed. Male patients who were> 40 years old with available pre- and posttransplant serum total prostate-specific antigen levels were included in the study. ...
Source: Clinical Prostate Cancer - April 4, 2018 Category: Cancer & Oncology Authors: Tonyali S, Aksoy E, Sobaci E, Akdogan M, Ceylan C, Bostancı EB, Akoglu M Tags: Exp Clin Transplant Source Type: research

Does 1.5  T mpMRI play a definite role in detection of clinically significant prostate cancer? Findings from a prospective study comparing blind 24-core saturation and targeted biopsies with a novel data remodeling model.
CONCLUSIONS: In patients with suspected PC and a previous negative PBx, a normal mpMRI may exclude a clinically significant PC, avoiding sPBx. PMID: 29616473 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 3, 2018 Category: Cancer & Oncology Authors: Dal Moro F, Zecchini G, Morlacco A, Gardiman MP, Lacognata CS, Lauro A, Rugge M, Prayer Galetti T, Zattoni F Tags: Aging Clin Exp Res Source Type: research

SGK1 inhibition-induced autophagy impairs prostate cancer metastasis by reversing EMT.
CONCLUSIONS: Taken together, this study unveils a novel mechanism in which SGK1 functions as a tumor metastasis-promoting gene and highlights how co-targeting SGK1 and autophagy restrains cancer progression due to the amplified antimetastatic effects. PMID: 29609629 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 2, 2018 Category: Cancer & Oncology Authors: Liu W, Wang X, Wang Y, Dai Y, Xie Y, Ping Y, Yin B, Yu P, Liu Z, Duan X, Liao Z, Chen Y, Liu C, Li X, Tao Z Tags: J Exp Clin Cancer Res Source Type: research

Role of Stromal Paracrine Signals in Proliferative Diseases of the Aging Human Prostate.
Abstract Androgens are essential for the development, differentiation, growth, and function of the prostate through epithelial-stromal interactions. However, androgen concentrations in the hypertrophic human prostate decrease significantly with age, suggesting an inverse correlation between androgen levels and proliferative diseases of the aging prostate. In elderly males, age- and/or androgen-related stromal remodeling is spontaneously induced, i.e., increased fibroblast and myofibroblast numbers, but decreased smooth muscle cell numbers in the prostatic stroma. These fibroblasts produce not only growth factors, ...
Source: Clinical Prostate Cancer - April 2, 2018 Category: Cancer & Oncology Authors: Ishii K, Takahashi S, Sugimura Y, Watanabe M Tags: J Clin Med Source Type: research

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Abstract Purpose This clinical practice guideline addresses abiraterone or docetaxel with androgen-deprivation therapy (ADT) for metastatic prostate cancer that has not been treated (or has been minimally treated) with testosterone-lowering agents. Methods Standard therapy for newly diagnosed metastatic prostate cancer has been ADT alone. Three studies have compared ADT alone with ADT and docetaxel, and two studies have compared ADT alone with ADT and abiraterone. Results Three prospective randomized studies (GETUG-AFU 15, STAMPEDE, and CHAARTED) examined overall survival (OS) with adding docetaxel to ADT. STAMPED...
Source: Clinical Prostate Cancer - April 2, 2018 Category: Cancer & Oncology Authors: Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, Celano P, Bangs R, Milowsky MI Tags: J Clin Oncol Source Type: research

A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97.
Conclusions: Our findings demonstrate the advantages of using a combinatory approach to identify microRNAs downregulated due to aberrant promoter methylation. MiR-152-3p downregulation and promoter methylation was found to be prevalent in primary PCa, which impairs its role in control of cell viability, cell cycle regulation and invasion. PMID: 29599847 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - April 1, 2018 Category: Cancer & Oncology Authors: Ramalho-Carvalho J, Gonçalves CS, Graça I, Bidarra D, Pereira-Silva E, Salta S, Godinho MI, Gomez A, Esteller M, Costa BM, Henrique R, Jerónimo C Tags: Clin Epigenetics Source Type: research

Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study.
Abstract PURPOSE: We investigated the oncologic effect of palliative transurethral resection of the prostate (pTURP) in patients with prostate cancer who received primary androgen deprivation therapy. METHODS: We reviewed 614 patients, including 83 who underwent pTURP; those with incidental prostate cancer were excluded. Patients were divided into the TURP group and non-TURP group. Propensity score matching was performed for comorbidity, initial prostate-specific antigen (PSA), TNM stage, and Gleason score (GS). The Kaplan-Meier method was used to confirm castration-resistant prostate cancer (CRPC), cancer-sp...
Source: Clinical Prostate Cancer - March 22, 2018 Category: Cancer & Oncology Authors: Choi SY, Ryu J, You D, Jeong IG, Hong JH, Ahn H, Kim CS Tags: J Cancer Res Clin Oncol Source Type: research

Impact of comorbidities at diagnosis on prostate cancer treatment and survival.
CONCLUSIONS: The results of the current study suggest that chronological age is a stronger predictor of treatment choices than comorbidities, although comorbidities have a larger influence on patients' mortality. Hence, inclusion of comorbidities in treatment choices may provide more appropriate treatment for PCa patients to counteract over- or undertreatment. PMID: 29417258 [PubMed - indexed for MEDLINE] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 22, 2018 Category: Cancer & Oncology Authors: Matthes KL, Limam M, Pestoni G, Held L, Korol D, Rohrmann S Tags: J Cancer Res Clin Oncol Source Type: research

Reversible intrahepatic cholestasis in metastatic prostate cancer: An uncommon paraneoplastic syndrome.
Abstract As with other genitourinary malignancies, a variety of paraneoplastic syndromes have been revealed to occur in patients with prostate cancer. Stauffer's Syndrome is a well-described clinical syndrome which manifests via intrahepatic cholestasis in patients with renal cell carcinoma. Less common is intrahepatic cholestasis occurring in association with prostate cancer. The current case report discusses a 67-year-old man presenting with liver failure secondary to intrahepatic cholestasis co-existing with metastatic prostate adenocarcinoma. The patient's liver failure completely resolved with androgen-depriv...
Source: Clinical Prostate Cancer - March 21, 2018 Category: Cancer & Oncology Authors: Bhangoo MS, Cheng B, Botta GP, Thorson P, Kosty MP Tags: Mol Clin Oncol Source Type: research

BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib.
This study examined the expression of B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra large (BCL-XL), two important anti-apoptosis factors that are also capable of inhibiting cell proliferation via accelerated G1 arrest or delayed G1/S transition, using immunostaining in simple prostatectomy BPH specimens from patients naïve to androgen manipulation. Since androgens and inflammation are thought to play important roles in BPH pathogenesis, we tested the effect of inhibiting 5a-reductase and/or COX-2 on the expression of BCL-2 and BCL-XL in BPH specimens from prostate cancer patients with BPH. These patients had no ...
Source: Clinical Prostate Cancer - March 15, 2018 Category: Cancer & Oncology Authors: Li F, Pascal LE, Zhou J, Zhou Y, Wang K, Parwani AV, Dhir R, Guo P, He D, Nelson JB, Wang Z Tags: Am J Clin Exp Urol Source Type: research

Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
Abstract Purpose Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic hormone-sensitive prostate cancer improves overall survival as compared with androgen deprivation therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+D and those who were treated with ADT alone. Methods Men were randomly assigned to ADT+ D (six cycles) or to ADT alone. QOL was assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Taxane, Functional Assessment of Chronic Illness Therapy-...
Source: Clinical Prostate Cancer - March 9, 2018 Category: Cancer & Oncology Authors: Morgans AK, Chen YH, Sweeney CJ, Jarrard DF, Plimack ER, Gartrell BA, Carducci MA, Hussain M, Garcia JA, Cella D, DiPaola RS, Patrick-Miller LJ Tags: J Clin Oncol Source Type: research

Marital relationship and health-related quality of life of patients with prostate cancer and their spouses: A longitudinal clinical study.
CONCLUSIONS: The results of this study add to current knowledge of the marital relationship of patients with prostate cancer and their spouses. The spouses reported that their marital relationship had suffered, whereas the patients reported that the marital relationship remained unchanged. RELEVANCE TO CLINICAL PRACTICE: These findings may be useful when counselling of patients with prostate cancer and their spouses. This article is protected by copyright. All rights reserved. PMID: 29516564 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 8, 2018 Category: Cancer & Oncology Authors: Harju E, Rantanen A, Helminen M, Kaunonen M, Isotalo T, Åstedt-Kurki P Tags: J Clin Nurs Source Type: research

Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.
CONCLUSION: HDDA10 is of added value to GG and other clinical-pathological parameters in predicting BCR and Mets endpoint, especially in the low to intermediate patients' risk groups. HDDA10 prognostic value should be further validated prospectively in stratifying patients specifically in low to intermediate GS (GG1-2), such as active surveillance programs. PMID: 29511883 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - March 6, 2018 Category: Cancer & Oncology Authors: Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, Karnes RJ, Bismar TA Tags: J Cancer Res Clin Oncol Source Type: research

Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10  ng/ml?
Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml? J Cancer Res Clin Oncol. 2018 Mar 05;: Authors: Xu N, Wu YP, Chen DN, Ke ZB, Cai H, Wei Y, Zheng QS, Huang JB, Li XD, Xue XY Abstract PURPOSE: To explore the value of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2) for predicting prostate biopsy results in patients with prostate specific antigen (PSA) levels of 4-10 ng/ml. METHODS: We retrospectively reviewed multi-parameter magnetic resonance images from 528 patients with PSA levels of 4-...
Source: Clinical Prostate Cancer - March 5, 2018 Category: Cancer & Oncology Authors: Xu N, Wu YP, Chen DN, Ke ZB, Cai H, Wei Y, Zheng QS, Huang JB, Li XD, Xue XY Tags: J Cancer Res Clin Oncol Source Type: research

Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy.
Sampo A Abstract Transrectal prostate biopsies carry the risk of infection. By using non-selective culture plates, instead of commonly used ciprofloxacin (CIP)-containing plates, we analyzed the association between Escherichia coli CIP minimal inhibitory concentration (MIC) and post-biopsy infectious complications. A pre-biopsy rectal swab was taken from 207 consecutive men, scheduled for transrectal 12-core prostate biopsy with CIP 750 mg as the mostly used prophylaxis. CIP MIC of rectal Gram-negative bacilli was determined from a chromogenic agar. Rectal E. coli were categorized to resistant (R) and interme...
Source: Clinical Prostate Cancer - March 2, 2018 Category: Cancer & Oncology Authors: Kalalahti I, Huotari K, Lahdensuo K, Tarkka E, Santti H, Rannikko A, Pätäri-Sampo A Tags: Eur J Clin Microbiol Infect Dis Source Type: research

Telomere biology and age-related diseases.
n W Abstract Telomeres are the protective end caps of chromosomes and shorten with every cell division. Telomere length has been proposed as a biomarker of biological age and a risk factor for age-related diseases. Epidemiologic studies show an association between leukocyte telomere length (LTL) and mortality. There is solid evidence that links LTL with cardiovascular disease. Short telomeres promote atherosclerosis and impair the repair of vascular lesions. Alzheimer's disease patients have also a reduced LTL. Telomeres measured in tumor tissue from breast, colon and prostate are shorter than in healthy tissue fr...
Source: Clinical Prostate Cancer - March 1, 2018 Category: Cancer & Oncology Authors: Herrmann M, Pusceddu I, März W, Herrmann W Tags: Clin Chem Lab Med Source Type: research

Prostate Cancer Screening.
Abstract During the prostate-specific antigen-based prostate cancer (PCa) screening era there has been a 53% decrease in the US PCa mortality rate. Concerns about overdiagnosis and overtreatment combined with misinterpretation of clinical trial data led to a recommendation against PCa screening, resulting in a subsequent reversion to more high-risk disease at diagnosis. Re-evaluation of trial data and increasing acceptance of active surveillance led to a new draft recommendation for shared decision making for men aged 55 to 69 years old. Further consideration is needed for more intensive screening in men with...
Source: Clinical Prostate Cancer - February 7, 2018 Category: Cancer & Oncology Authors: Catalona WJ Tags: Med Clin North Am Source Type: research

Prostate Cancer: A Contemporary Approach to Treatment and Outcomes.
Abstract Given the high incidence of prostate cancer and the need for shared decision-making before screening, it is imperative that primary care providers understand treatment options and treatment adverse effects. In this review article, the treatment options for the localized and metastatic prostate cancer are discussed, including the different modalities and their indications, adverse effects, oncologic outcomes, posttreatment monitoring, and potential treatment options following cancer recurrence. PMID: 29406054 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 7, 2018 Category: Cancer & Oncology Authors: Weiner AB, Kundu SD Tags: Med Clin North Am Source Type: research

Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
PMID: 29401003 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 5, 2018 Category: Cancer & Oncology Authors: Faiena I, Holden S, Cooperberg MR, Holden S, Soule HR, Simons JW, Morgan TM, Penson DF, Morgans AK, Hussain M Tags: J Clin Oncol Source Type: research

Circulating vitamin D concentration and risk of prostate cancer: a dose-response meta-analysis of prospective studies.
Conclusion: The findings suggest that highest 25[OH]D concentration is correlated with elevated risk of prostate cancer and a modest dose-response effect exists in this association; however, more studies are needed. PMID: 29386901 [PubMed] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 3, 2018 Category: Cancer & Oncology Authors: Gao J, Wei W, Wang G, Zhou H, Fu Y, Liu N Tags: Ther Clin Risk Manag Source Type: research

Re-Creating the Urinary Tract: An Art Derived from Science.
PMID: 29169455 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - November 26, 2017 Category: Cancer & Oncology Authors: Taneja SS Tags: Urol Clin North Am Source Type: research

Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
Abstract PET/CT-guided interventions using specific radiotracers are promising for detecting avid lesions not well visualized with other imaging methods. A 72-year-old man who initially presented with prostate cancer Gleason 5 + 4 (prostate-specific antigen [PSA] = 7.9 ng/mL) underwent radical prostatectomy and node dissection. Three years after radiation, a rising PSA was observed over 6 months with PSA level reaching 1.08 ng/mL. He was evaluated with prostate-specific membrane antigen-based (PSMA) F-DCFPyL PET/CT, conventional CT, F-FDG PET/CT, and C-choline PET/CT. The PSMA F-DCFPyL PET/CT successfully targeted...
Source: Clinical Prostate Cancer - November 5, 2017 Category: Cancer & Oncology Authors: Cornelis FH, Durack JC, Morris MJ, Scher HI, Solomon SB Tags: Clin Nucl Med Source Type: research

Significance of long chain polyunsaturated fatty acids in human health.
odríguez C Abstract In the last decades, the development of new technologies applied to lipidomics has revitalized the analysis of lipid profile alterations and the understanding of the underlying molecular mechanisms of lipid metabolism, together with their involvement in the occurrence of human disease. Of particular interest is the study of omega-3 and omega-6 long chain polyunsaturated fatty acids (LC-PUFAs), notably EPA (eicosapentaenoic acid, 20:5n-3), DHA (docosahexaenoic acid, 22:6n-3), and ARA (arachidonic acid, 20:4n-6), and their transformation into bioactive lipid mediators. In this sense, new f...
Source: Clinical Prostate Cancer - July 30, 2017 Category: Cancer & Oncology Authors: Zárate R, El Jaber-Vazdekis N, Tejera N, Pérez JA, Rodríguez C Tags: Clin Transl Med Source Type: research

Integrating phosphoproteomics into the clinical management of prostate cancer.
Abstract Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phosphoproteomic technology with genomic assays to s...
Source: Clinical Prostate Cancer - February 17, 2017 Category: Cancer & Oncology Authors: Cheng LC, Tan VM, Ganesan S, Drake JM Tags: Clin Transl Med Source Type: research

The Big 3: An Updated Overview of Colorectal, Breast, and Prostate Cancers.
This article provides a current overview of colorectal, breast, and prostate cancers. For each cancer, data related to incidence and prevalence are discussed, as well as nonmodifiable and modifiable risk factors. Information about detection and evidenced-based screening guideline recommendations is reviewed, with the most common and recent treatment modalities emphasized. Current clinical and treatment-related issues are discussed along with nursing care and implications for cancer care. Future directions for these 3 cancers are addressed also. PMID: 28189165 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 14, 2017 Category: Cancer & Oncology Authors: Gordon J, Fischer-Cartlidge E, Barton-Burke M Tags: Nurs Clin North Am Source Type: research

Prostate MR Imaging: An Update.
Abstract Improvements in prostate MR imaging techniques and the introduction of MR imaging-targeted biopsies have had central roles in prostate cancer (PCa) management. The role of MR imaging has progressed from largely staging patients with biopsy-proven PCa to detecting, characterizing, and guiding the biopsy of suspected PCa. These diagnostic advances, combined with improved therapeutic interventions, have led to a more sophisticated and individually tailored approach to patients' unique PCa profile. This review discusses the MR imaging, a standardized reporting scheme, and the role of fusion-targeted prostate ...
Source: Clinical Prostate Cancer - January 28, 2017 Category: Cancer & Oncology Authors: Shaish H, Taneja SS, Rosenkrantz AB Tags: Radiol Clin North Am Source Type: research

Diffusion-Weighted Genitourinary Imaging.
hoeny H Abstract This review article aims to provide an overview on of diffusion-weighted MR imaging (DW-MR imaging) in the urogenital tract. Compared with conventional cross-sectional imaging methods, the additional value of DW-MR imaging in the detection and further characterization of benign and malignant lesions of the kidneys, bladder, prostate, and pelvic lymph nodes is discussed as well as the role of DW-MR imaging in the evaluation of treatment response. PMID: 28126222 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 28, 2017 Category: Cancer & Oncology Authors: Maurer MH, Härmä KH, Thoeny H Tags: Radiol Clin North Am Source Type: research

Distress During Radiation Therapy: Assessment Among Patients With Breast or Prostate Cancer 
.
Distress During Radiation Therapy: Assessment Among Patients With Breast or Prostate Cancer
. Clin J Oncol Nurs. 2017 Feb 01;21(1):93-98 Authors: Stapleton SJ, Valerio TD, Astroth K, Woodhouse S Abstract BACKGROUND: Distress is regarded as the sixth vital sign in cancer care, but few studies describe distress in patients undergoing radiation therapy. 
. OBJECTIVES: The purpose of this study was to assess distress levels among patients with breast or prostate cancer undergoing radiation therapy and investigate which problems contribute to patients' distress levels. 
. METHODS: A retrosp...
Source: Clinical Prostate Cancer - January 22, 2017 Category: Cancer & Oncology Authors: Stapleton SJ, Valerio TD, Astroth K, Woodhouse S Tags: Clin J Oncol Nurs Source Type: research

Prostate cancer, PI3K, PTEN and prognosis.
Abstract Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most common driving events in prostate cancer development. The observed mechanisms of PTEN loss are diverse, but both homozygous and heterozygous genomic deletions including PTEN are frequent, and often accompanied by loss of detectable protein as assessed by immunohistochemistry (IHC). The occurrence of PTEN loss is highest in aggressive metastatic disease and this has driven the development of PTEN as a prognostic biomarker, either a...
Source: Clinical Prostate Cancer - January 9, 2017 Category: Cancer & Oncology Authors: Wise HM, Hermida MA, Leslie NR Tags: Clin Sci (Lond) Source Type: research

Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.
Abstract The treatment of elderly patients with cancer is usually viewed by clinicians as a challenge, because of the age-related decline in normal organ function and the frequent concomitant administration of multiple drugs for comorbid conditions. Clinicians therefore tend not to prescribe antineoplastic agents (mainly in the case of chemotherapy) to elderly patients, with the fear of excess toxicity leading to an unfavorable cost:benefit ratio. The cutoff age defining a cancer patient as elderly is usually 70 years, but over the last 10 years clinicians have paid more attention to functional status, as evaluate...
Source: Clinical Prostate Cancer - January 7, 2017 Category: Cancer & Oncology Authors: Caffo O, Maines F, Rizzo M, Kinspergher S, Veccia A Tags: Clin Interv Aging Source Type: research

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer.
Abstract Prostate cancer is the second most diagnosed cancer in males in the world. Plasma quantification of prostate-specific antigen substantially improved the early detection of prostate cancer, but still lacks the required specificity. Clinical management of prostate cancer needs advances in the development of new non-invasive biomarkers, ameliorating current diagnosis and prognosis and guiding therapeutic decisions. microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level. These miRNAs are expressed in the cells and are also present in cell-derive...
Source: Clinical Prostate Cancer - January 3, 2017 Category: Cancer & Oncology Authors: Valentino A, Reclusa P, Sirera R, Giallombardo M, Camps C, Pauwels P, Crispi S, Rolfo C Tags: Clin Transl Oncol Source Type: research

Monte Carlo Decision Curve Analysis Using Aggregate Data.
CONCLUSIONS: We provide a simple, easy-to-use model, which can facilitate wider use of DCA and better evaluation of diagnostic tests and predictive models that rely only on aggregate data reported in literature. This article is protected by copyright. All rights reserved. PMID: 28042671 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 1, 2017 Category: Cancer & Oncology Authors: Hozo I, Tsalatsanis A, Djulbegovic B Tags: Eur J Clin Invest Source Type: research

The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
CONCLUSIONS: The present study showed a significantly high PSA response compared with previous reports. Most patients tolerated the protocol treatment well, whereas hematotoxicity was often observed. PMID: 28042138 [PubMed - as supplied by publisher] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y Tags: Jpn J Clin Oncol Source Type: research

Can Prostate Cancer Really Respond to Immunotherapy?
PMID: 28034060 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Kim W, Fong L Tags: J Clin Oncol Source Type: research

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial-There is No Significant Reduction in Death (Yet).
PMID: 28034067 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Michels J Tags: J Clin Oncol Source Type: research

Does Enzalutamide Really Reduce the Risk of Progression Compared With Bicalutamide in Patients With Castration-Resistant Prostate Cancer?
ın B PMID: 28034074 [PubMed - in process] (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - December 31, 2016 Category: Cancer & Oncology Authors: Şendur MA, Yalçın B Tags: J Clin Oncol Source Type: research